AI Summary

A team led by Professor Yong Taik Lim at Sungkyunkwan University’s SKKU Advanced Institute of Nanotechnology has created an engineered nanoplatform called t‑SMC (trained immunity‑mediated splenic myelopoiesis converter). The platform targets the spleen to shift splenic myelopoiesis from a protumoral to an antitumoral immune phenotype. Tumor growth normally hijacks splenic myeloid cells, turning them into cells that support tumor growth and impair systemic immunity. By reprogramming these cells, t‑SMC aims to reduce tumor recurrence and metastasis after primary tumor removal. The work is reported in Advanced Materials.

AI summaries can be wrong sometimes—always verify important details using the source article.